Could an antiviral treat depression? small trial tests the idea
NCT ID NCT04724447
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether the antiviral drug valganciclovir can improve depression symptoms and reduce brain inflammation in people with major depressive disorder who also have a common virus called CMV. Twenty participants took either the drug or a placebo for 8 weeks, and researchers measured changes in brain scans, blood inflammation, and mood. The trial is small and early-stage, so results are preliminary.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Valganciclovir (antiviral drug)
- What this could lead to
- If it works, this could point toward a new treatment for depression in people with chronic CMV infection.
- What could go wrong
- This is a very small early-phase trial with only 20 people, so results may not apply widely. The drug also has side effects and may not improve depression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Laureate Institute for Brain Research
Tulsa, Oklahoma, 74136, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a structured care pathway ease teen depression?
- Can a nasal spray break through tough depression?
- Could a new drug offer hope for Treatment-Resistant depression?
- Targeting depression: can MRI-Guided brain zaps rewire key circuits?
- Can a psychedelic trip plus a gentle ear zap lift depression?
- Can a smart brain implant outsmart depression?